Do the selective COX2 inhibitors have a lower risk for gastrointestinal toxicity compared to the traditional nonsteroidal antiinflammatory drugs?
Yes. The COX2 inhibitors were associated with a lower incidence of symptomatic ulcers compared with traditional NSAIDs at standard doses. The decrease in upper GI toxicity was strongest among patients not taking aspirin concomitantly.
